

# THE ANNUAL COMBINED NORTHERN AND YORKSHIRE RHEUMATOLOGY MEETING

NATIONAL RAILWAY MUSEUM, YORK

WEDNESDAY SEPTEMBER 26<sup>th</sup> 2018

**0830-0915 BREAKFAST, REGISTRATION AND COFFEE**

**0915-1035 CONCURRENT TRANSLATIONAL & CLINICAL CASE SESSION**

*Translational science abstracts*

*Chair Dr Ed Vital*

## **Lymphocyte DNA Methylation as a Mediator of Genetic Risk in Rheumatoid Arthritis**

Clark AD<sup>1</sup>, Nair N<sup>1</sup>, Skelton, AJ<sup>1</sup>, Anderson AE<sup>1</sup>, Thalayasingam N<sup>1</sup>, Naamane N<sup>1</sup>, Diboll J<sup>1</sup>, Massey J<sup>2</sup>, Eyre S<sup>2</sup>, Barton, A<sup>2</sup>, Isaacs JD<sup>1</sup>, Reynard LN<sup>3</sup>, Pratt AG<sup>1</sup>

<sup>1</sup>Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals & University; <sup>2</sup>Institute of Inflammation & Repair and NIHR Manchester Musculoskeletal BRU, Central Manchester NHS Trust & Manchester University; <sup>3</sup>Institute of Genetic Medicine, Newcastle University.

## **Flow Cytometric Immunophenotyping of Salivary Glands in Primary Sjögren's Syndrome**

Paul Milne<sup>1</sup>, Aleksandra Ivovic<sup>2/4</sup>, Emmanuella Traianos<sup>3</sup>, David Storey<sup>3</sup>, Jessica Tarn<sup>3</sup>, Richard Siegal<sup>4</sup>, Peter Campbell<sup>2</sup>, Wan-Fai Ng<sup>3</sup> & Matthew Collin<sup>1</sup>.

<sup>1</sup>Human Dendritic Cell Lab, Institute of Cellular Medicine, Newcastle University, UK; <sup>2</sup>Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, UK; <sup>3</sup>Wellcome Sanger Institute, Cambridge, UK; <sup>4</sup>Autoimmunity Branch, National Institutes of Health, Bethesda, Maryland, USA.

## **Investigating potential differences in mesenchymal stromal cells in medial and lateral condyles in patients with knee osteoarthritis**

Clara Sanjurjo-Rodriguez, Thomas Baboolal, Agata Burska, Frederique Ponchel, Owen Wall, Joseph Aderinto, Hemant Pandit, Dennis McGonagle, Elena Jones

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

## **Exploring PIM1 as a measurable therapeutic target in early rheumatoid arthritis.**

Nicola J Maney, Amy E Anderson, John D Isaacs, Arthur G Pratt

Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals & University

## **Disentangling mononuclear phagocyte heterogeneity in rheumatoid arthritis synovial fluid through single cell transcriptomics**

<sup>1</sup>Reynolds G, <sup>1</sup>Stephenson E, <sup>1</sup>Botting R, <sup>1</sup>Maunder D, <sup>1</sup>Fletcher J, <sup>1</sup>Vegh P, <sup>1</sup>Hilkens C, <sup>2</sup>Villani AC, <sup>3</sup>Teichmann S, <sup>1</sup>Isaacs JD, <sup>1</sup>Haniffa MA

<sup>1</sup>Institute of Cellular Medicine, University of Newcastle upon Tyne, <sup>2</sup>Massachusetts General Hospital, Boston, <sup>3</sup>Wellcome Sanger Institute Hinxton.

This meeting has been sponsored by Abbvie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Roche & Chugai and UCB. None of the companies have had any input into the educational content of this meeting.

**In SLE patients in sustained low disease activity, novel interferon assays predict flares and glucocorticoid requirements**

K. Dutton, A. Psarras, Y. El-Sherbiny, M. Y. Md Yusof, P. Emery, E. Vital  
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

***Clinical Case abstracts in Acute ward referral case and urgent presentations***

***Chairs: Dr Alice Lorenzi and Dr Mike Green***

**Case 1/2 Noora Soobraty**

**Case 2/3 Jessica Weightman**

**Case 5 'A case to learn from' - Smrity Smrity, Maria Slade and Andy Gough**

**1035-1105 TEA AND COFFEE**

**1105-1150 CELEBRATING LOCAL EXPERTISE**

***Chair Prof Phil Conaghan***

**Dr. James Miller,**

Consultant Neurologist, Newcastle upon Tyne Hospitals Foundation Trust.  
*Emerging concepts in treatment and management of myositis (TBC)*

**1150-1230 TRANSLATIONAL MUSCULOSKELETAL SCIENCE ABSTRACTS**

**The potential role of shear wave elastography for diagnosing idiopathic inflammatory myopathies**

Abdulrahman Alfuraih<sup>1,2,3</sup>, Ai Lyn Tan<sup>\*2,3</sup>, Philip O'Connor<sup>3</sup>, Paul Emery<sup>2,3</sup>, Richard Wakefield<sup>2,3</sup>.

<sup>1</sup>Prince Sattam bin Abdulaziz University, Kharij, Saudi Arabia; <sup>2</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; <sup>3</sup>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

**Patients with ultrasound-detected shoulder pathologies cluster into groups with different clinical associations**

Tran G<sup>1,2</sup>, Hensor EMA<sup>1,2</sup>, Kingsbury SR<sup>1,2</sup>, Conaghan PG<sup>1,2,3</sup>

<sup>1</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; <sup>2</sup>NIHR Leeds Biomedical Research Centre, University of Leeds, Leeds, UK; <sup>3</sup>Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Nottingham, UK

**In RA patients with initial response to rituximab, early depth of B-cell depletion is associated with long term maintenance of therapy**

L Garcia Montoya<sup>1,2</sup>, M.Y. Md Yusof<sup>1,2</sup>, J.-B. Candelier<sup>1,2</sup>, P. Pentony<sup>1,2</sup>, L. Duquenne<sup>1,2</sup>, A.C. Rawstron<sup>1,2</sup>, E.M. Vital<sup>1,2</sup>, P. Emery<sup>1,2</sup>

<sup>1</sup>Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds; <sup>2</sup>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

**1230-1335 LUNCH (Station Hall)**

This meeting has been sponsored by Abbvie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Roche & Chugai and UCB. None of the companies have had any input into the educational content of this meeting.

## 1335-1535 EMERGING CONCEPTS IN SPONDYLOARTHROPATHY.

*Chair Dr Arthur Pratt and Dr Fiona Rayner*

### **Emergence of severe spondyloarthropathy related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease**

S. Dubash<sup>1,2</sup>, T. Marianayagam<sup>4</sup>, I. Tinazzi<sup>5</sup>, T. Al-Araimi<sup>6</sup>, C. Pagnoux<sup>6</sup>, A. V. Weizman<sup>7</sup>, P. Richette<sup>8</sup>, M.-L. Tran Minh<sup>9</sup>, M. Allez<sup>9</sup>, A. Singh<sup>10</sup>, F. Ciccia<sup>11</sup>, J Hamlin<sup>3</sup>, A. L. Tan<sup>1,2</sup>, H. Marzo-Ortega<sup>1,2</sup>, D. McGonagle<sup>1,2</sup>

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

***Helena Marzo-Ortega to present***

### **Fevers and Liver Disease - Systemic Involvement in Axial Spondyloarthritis or something else altogether?**

J Weightman<sup>1</sup>, J Dyson<sup>2</sup>, B Thompson<sup>1</sup>

Department of Rheumatology<sup>1</sup> and Gastroenterology and Liver Unit<sup>2</sup> Freeman Hospital, Newcastle upon Tyne

### **Personalising care: using infliximab drug trough and anti-drug antibody levels is a safe and cost effective treatment strategy in Spondyloarthritis**

S. Dubash<sup>1,2</sup>, J Fitton<sup>1,2</sup>, D Bryer<sup>1</sup>, A Barr<sup>1,2</sup>, C Vandeveld<sup>1,2</sup>, H Marzo-Ortega<sup>1,2</sup>, JE Freeston<sup>1,2</sup>

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

***Jane Freeston to present***

## 1410-1455 KEYNOTE SPEAKER

*Dr Arthur Pratt to introduce*

### **Dr. Stefan Siebert,**

Senior Clinical Lecturer, University of Glasgow.

*PsA comorbidities: more than just cardiovascular disease.*

### **Noninvasive diagnostic approaches for psoriasis and lupus erythematosus**

Anna Berekmeri<sup>1,2\*</sup>, Mohammad Shalbaf<sup>1\*</sup>, Adewonuola Alase<sup>1</sup>, Yuzaiful MD Yusof<sup>1,2</sup>, Tom Macleod<sup>3</sup>, Mark Goodfield<sup>4</sup>, Philip Laws<sup>4</sup>, Philip Helliwell<sup>5</sup>, Natalia V. Botchkareva<sup>6</sup>, Edward M. Vital<sup>1,2</sup>, Martin Stacey<sup>3</sup>, Miriam Wittmann<sup>1,2</sup>

<sup>1</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; <sup>2</sup>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust; <sup>3</sup> Faculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds; <sup>4</sup> Department of Dermatology, Leeds Teaching Hospitals NHS Trust; <sup>5</sup> Bradford Teaching Hospitals Foundation Trust; <sup>6</sup> Centre for Skin Sciences, University of Bradford  
\*equal contribution

***Adewonuola Alase to present***

### **Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): first results from a proof-of-concept phase 2 trial**

Md Yuzaiful Md Yusof, Miriam Wittmann, Catherine Fernandez, Duncan Wilson, Sara Edward, Giuseppina Abignano, Adewonuola Alase, Linda Sharples, Phil Laws, M J Goodfield, Edward M Vital, Paul Emery

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

This meeting has been sponsored by Abbvie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Roche & Chugai and UCB. None of the companies have had any input into the educational content of this meeting.

**On tapering therapy for RA patients in clinical remission; flare on cs-DMARDs predicted by clinical features and ultrasound, whereas T-cell abnormalities predictive for b-DMARD tapering**

Dr Hanna Gul, Dr Frederique Ponchel, Professor Paul Emery  
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

**1535-1605 TEA AND COFFEE**

**1605-1650 CELEBRATING LOCAL EXPERTISE**

*Chair Prof Fai Ng*

**Prof Ann Morgan**

Professor of Molecular Rheumatology/ Hon. Consultant Rheumatologist  
Leeds Institute Rheumatic and Musculoskeletal Medicine  
*Therapeutic targeting of the Fcγ Receptors:  
From clinical observations to novel therapeutic strategies*

**1650-1730 JEWELS IN THE CROWN**

**Infection risk associated with oral glucocorticoid dose in people with polymyalgia rheumatica and giant cell arteritis in England**

Mar Pujades-Rodriguez<sup>1</sup>, Jianhua Wu<sup>1</sup>, Adam Keeley<sup>1</sup>, Christian Mallen<sup>2</sup>, Ann W Morgan<sup>1,3</sup>

<sup>1</sup>. University of Leeds, UK; <sup>2</sup>. University of Keele, UK; <sup>3</sup>. Leeds Teaching Hospitals NHS Trust, UK

**PRIZE WINNING TRANSLATIONAL ABSTRACT**

*Professor Ann Morgan to present prize*

**The role of skin tissue in initiation of SLE**

Antonios Psarras, Adewuonola Alase, Md Yuzaiful Md Yusof, Mohammed Shalbah, Paul Emery, Miriam Wittmann, Edward M Vital

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust

**PRIZE WINNING CLINICAL ABSTRACT**

*Dr Bridget Griffiths to present prize*

**An Increased Prevalence of Periodontal Disease, *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans* in anti-CCP positive individuals At-Risk of Inflammatory Arthritis**

K Mankia, Z Cheng, T Do, J Kang, L Hunt, J Meade, V Clerehugh, A Speirs, A Tugnait, E Hensor, D Devine, P Emery

**1730 Wrap up and close**

This meeting has been sponsored by Abbvie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Roche & Chugai and UCB. None of the companies have had any input into the educational content of this meeting.